Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
2019 · The Lancet · 2,820 citations
https://doi.org/10.1016/s0140-6736(19)31149-3
C
Cesar Javier Zaidman
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
32
Papers
9.9K
Citations
24
h-index
29
i10-index
Cesar Javier Zaidman is an academic researcher from Çevre, Şehircilik ve İklim Değişikliği Bakanlığı. The author has contributed to research in topics: Diabetes Treatment and Management & Lipoproteins and Cardiovascular Health & Diabetes Management and Research. The author has an h-index of 24, co-authored 28 publications.
Papers by this author
worksAlbiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial
2018 · The Lancet · 1,728 citations
https://doi.org/10.1016/s0140-6736(18)32261-x
Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial
2019 · The Lancet · 600 citations
https://doi.org/10.1016/s0140-6736(19)31150-x
Global Variations in Heart Failure Etiology, Management, and Outcomes
2023 · JAMA · 136 citations
https://doi.org/10.1001/jama.2023.5942
Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol
2021 · Journal of the American College of Cardiology · 131 citations
https://doi.org/10.1016/j.jacc.2021.04.102
Design and baseline characteristics of the Finerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic Kidney Disease (FIND-CKD) randomized trial
2024 · Nephrology Dialysis Transplantation · 63 citations
https://doi.org/10.1093/ndt/gfae132
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat